Precision BioSciences (DTIL) Stock Price, News & Analysis

Company Overview

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area. The company completed a business combination with a special purpose acquisition company (SPAC) in 2021 and began trading on the Nasdaq under the ticker DTIL. Over its history, Precision BioSciences has focused on optimizing ARCUS for high specificity, efficiency and manufacturability, laying the groundwork for scalable gene editing solutions.

Precision BioSciences is led by President and Chief Executive Officer Matt Kane, who has steered the company’s scientific and strategic initiatives since joining in 2014. Under his leadership, the company has established collaborations with academic institutions and biopharmaceutical partners to advance preclinical studies and clinical trials. With a focus on innovation and translational research, Precision BioSciences aims to bring next‐generation gene therapies from discovery through to regulatory approval and commercialization.

Key Stats

• Today's Range: $8.30 to $8.98
• 50-Day Range: $6.10 to $9.28
• 52-Week Range: $3.53 to $9.62
• Volume: 428,286 shs
• Average Volume: 326,108 shs
• Market Capitalization: $234.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.25
• Consensus Rating: Moderate Buy

Precision BioSciences Stock Analysis - MarketRank™

Precision BioSciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 628th out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Precision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Precision BioSciences has a consensus price target of $32.25, representing about 274.6% upside from its current price of $8.61.

Amount of Analyst Coverage

Precision BioSciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Precision BioSciences are expected to grow in the coming year, from ($3.39) to ($1.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Precision BioSciences is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Precision BioSciences is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Precision BioSciences has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.72% of the float of Precision BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Precision BioSciences has a short interest ratio ("days to cover") of 10.48, which indicates bearish sentiment.

Change versus previous month

Short interest in Precision BioSciences has recently increased by 20.71%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Precision BioSciences does not currently pay a dividend.

Dividend Growth

Precision BioSciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.45

News Sentiment

Precision BioSciences has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Precision BioSciences this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for DTIL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

1 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Precision BioSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.70% of the stock of Precision BioSciences is held by insiders.

Percentage Held by Institutions

37.99% of the stock of Precision BioSciences is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 8/19/2026
• Next Earnings (Estimated): 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DTIL
• CIK: 1357874
• Web: www.precisionbiosciences.com
• Phone: (919) 314-5512
• Fax: N/A
• Employees: 200
• Year Founded: 2006

Price Target and Rating

• Average Price Target for Precision BioSciences: $32.25
• High Price Target: $60.00
• Low Price Target: $19.00
• Potential Upside/Downside: +279.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.72 million
• Net Margins: -96.73%
• Pretax Margin: -119.00%
• Return on Equity: -72.52%
• Return on Assets: -32.25%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 12.82
• Quick Ratio: 12.82

Sales & Book Value

• Annual Sales: $34.26 million
• Price / Sales: 6.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.03 per share
• Price / Book: 2.11

Miscellaneous

• Outstanding Shares: 27,600,000
• Free Float: 26,857,000
• Market Cap: $234.60 million
• Optionable: No Data
• Beta: 1.27